AXIM Biotechnologies (AXIM) is actively researching and developing innovative pharmaceutical delivery systems and active pharmaceutical ingredients (APIs). They are a world leader in the R&D of cannabinoid-based pharmaceutical products and are headquartered in the US. AXIM recently launched its AXIM Wellness division tasked with bringing consumers premium cannabinoid-based nutraceutical products. This new division will utilize AXIM's patent on CBD-based chewing gums to expand its neutraceutical gum line, including products targeting migraines, smoking cessation, and overall wellness. In addition, AXIM is planning on expanding its presence in the oral care products market later this year.
| Loading Documents... |
